214 related articles for article (PubMed ID: 32581215)
21. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
[TBL] [Abstract][Full Text] [Related]
22. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
[No Abstract] [Full Text] [Related]
23. Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.
Sánchez J; Nicolini V; Fahrni L; Waldhauer I; Walz AC; Jamois C; Fowler S; Simon S; Klein C; Umaña P; Friberg LE; Frances N
AAPS J; 2022 Oct; 24(6):106. PubMed ID: 36207642
[TBL] [Abstract][Full Text] [Related]
24. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
25. Bispecific antibodies.
Brinkmann U; Kontermann RE
Science; 2021 May; 372(6545):916-917. PubMed ID: 34045345
[No Abstract] [Full Text] [Related]
26. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
27. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.
Teijeira A; Migueliz I; Garasa S; Karanikas V; Luri C; Cirella A; Olivera I; Cañamero M; Alvarez M; Ochoa MC; Rouzaut A; Rodriguez-Ruiz ME; Sanmamed MF; Klein C; Umaña P; Ponz M; Bacac M; Melero I
Theranostics; 2022; 12(3):1373-1387. PubMed ID: 35154495
[No Abstract] [Full Text] [Related]
28. In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
Lehmann S; Perera R; Grimm HP; Sam J; Colombetti S; Fauti T; Fahrni L; Schaller T; Freimoser-Grundschober A; Zielonka J; Stoma S; Rudin M; Klein C; Umana P; Gerdes C; Bacac M
Clin Cancer Res; 2016 Sep; 22(17):4417-27. PubMed ID: 27117182
[TBL] [Abstract][Full Text] [Related]
29. Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy.
Kujawski M; Li L; Bhattacharya S; Wong P; Lee WH; Williams L; Li H; Chea J; Poku K; Bowles N; Vaidehi N; Yazaki P; Shively JE
BMC Cancer; 2019 Sep; 19(1):882. PubMed ID: 31488104
[TBL] [Abstract][Full Text] [Related]
30. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
Int J Cancer; 1999 Jan; 80(1):138-44. PubMed ID: 9935244
[TBL] [Abstract][Full Text] [Related]
31. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
32. CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation.
Willems A; Schoonooghe S; Eeckhout D; De Jaeger G; Grooten J; Mertens N
Cancer Immunol Immunother; 2005 Nov; 54(11):1059-71. PubMed ID: 15891885
[TBL] [Abstract][Full Text] [Related]
33. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
[TBL] [Abstract][Full Text] [Related]
34. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
[TBL] [Abstract][Full Text] [Related]
35. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
[TBL] [Abstract][Full Text] [Related]
36. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.
Schreiner J; Thommen DS; Herzig P; Bacac M; Klein C; Roller A; Belousov A; Levitsky V; Savic S; Moersig W; Uhlenbrock F; Heinzelmann-Schwarz VA; Umana P; Pisa P; von Bergwelt-Baildon M; Lardinois D; Müller P; Karanikas V; Zippelius A
Oncoimmunology; 2016 Feb; 5(2):e1062969. PubMed ID: 27057429
[TBL] [Abstract][Full Text] [Related]
37. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
39. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
Park JA; Santich BH; Xu H; Lum LG; Cheung NV
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986124
[TBL] [Abstract][Full Text] [Related]
40. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
